Year-two patients are the best customers in GLP-1 telehealth — stable, low-touch, reliable — and the market splits on how to treat them: reward the loyalty, or quietly bank it. We compared how the major pricing structures handle maintenance. The differences compound to four figures over a year.
Key Takeaways
- Maintenance economics hinge on one fact: most maintainers use less medication — lower doses or stretched intervals — than year-one patients.
- Fair structures pass that through: dose-tier step-downs, flat annual pricing cheap enough to moot the question, or interval flexibility on your supply.
- Unfair structures charge peak-treatment prices for maintenance-level product and count on inertia.
- Best current answers: flat annual plans in the $49–$99 range, or tiered plans shopped at your known low dose.
The Maintenance Math Providers Don't Volunteer
A patient maintaining on 0.5–1.0mg consumes a fraction of the medication a 2.4mg patient does, with less clinical overhead. If your price didn't move when your dose did, the margin on you widened dramatically — the question is whether the pricing structure ever gives it back.
Structure 1: Flat Annual Pricing
At $49–$99/month on annual commitment, flat plans answer the fairness question by brute force: the price is low enough at every dose that dose-level fairness stops mattering. The trade is the commitment itself — fine for a stable maintainer who's proven the provider, wrong for someone still experimenting. Grade: A for settled maintainers.
Structure 2: Tiered Step-Down
Tiered plans finally shine in maintenance: you know your dose, so shop the exact tier. Low-dose tiers at $99–$149 month-to-month with zero commitment is a legitimately fair deal — if the provider lets you move down tiers as easily as up. Ask exactly that before assuming. Grade: B+, contingent on friction-free step-downs.
Structure 3: Interval Stretching on Flat Plans
Maintainers who stretch weekly injections to every 10–14 days (a common supervised pattern) effectively cut consumption 25–40%. On plans supplying vials, your supply simply lasts longer — a self-service discount. Confirm your provider's refill cadence follows usage rather than the calendar, or the savings ship themselves into your fridge as surplus. Grade: A when refills track usage; C when auto-ship ignores it.
Structure 4: Peak Pricing Forever
The inertia model: $249+ month-to-month regardless of dose, no maintenance tier, refills on rails. Every dollar of your reduced consumption is retained margin. Nothing illegal about it — just don't be the customer it's designed for. Grade: F for maintainers.
The Renewal-Day Playbook
- Know your actual monthly consumption (dose × frequency).
- Price your exact usage across two or three competitors — as a maintainer you're the easiest patient to onboard anywhere.
- Ask your current provider to match. Retention teams have latitude that list prices don't show.
Maintenance-Fair Programs We Track
Telos Rx — Semaglutide
Compounded semaglutide — from $49/mo on 12-month plans
Identical flat-at-every-dose structure on the semaglutide side.
Compounded medications are not FDA-approved.
Visit Telos Rx Paid linkTelos Rx — Tirzepatide
Compounded tirzepatide — from $49/mo on 12-month plans
$199 month-to-month sliding to $49/mo annual, flat at every dose, FSA/HSA accepted, cancel anytime.
Compounded medications are not FDA-approved.
Visit Telos Rx Paid linkWellorithm
Oral tablets — sema $147/mo, tirz $249/mo
Lowest published oral compounded pricing on our tracker.
Compounded medications are not FDA-approved.
Visit Wellorithm Paid linkVerdict: maintenance is where pricing structures reveal their character. You're the prize customer now — negotiate like it.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.